Literature DB >> 30808235

Five Years of Successful Inducible Transgene Expression Following Locoregional Adeno-Associated Virus Delivery in Nonhuman Primates with No Detectable Immunity.

Mickaël Guilbaud1, Marie Devaux1, Celia Couzinié1, Johanne Le Duff1, Alice Toromanoff1, Céline Vandamme1, Nicolas Jaulin1, Gwladys Gernoux1, Thibaut Larcher2, Philippe Moullier1, Caroline Le Guiner1, Oumeya Adjali1.   

Abstract

Anti-transgene immune responses elicited after intramuscular (i.m.) delivery of recombinant adeno-associated virus (rAAV) have been shown to hamper long-term transgene expression in large-animal models of rAAV-mediated gene transfer. To overcome this hurdle, an alternative mode of delivery of rAAV vectors in nonhuman primate muscles has been described: the locoregional (LR) intravenous route of administration. Using this injection mode, persistent inducible transgene expression for at least 1 year under the control of the tetracycline-inducible Tet-On system was previously reported in cynomolgus monkeys, with no immunity against the rtTA transgene product. The present study shows the long-term follow-up of these animals. It is reported that LR delivery of a rAAV2/1 vector allows long-term inducible expression up to at least 5 years post gene transfer, with no any detectable host immune response against the transactivator rtTA, despite its immunogenicity following i.m. gene transfer. This study shows for the first time a long-term regulation of muscle gene expression using a Tet-On-inducible system in a large-animal model. Moreover, these findings further confirm that the rAAV LR delivery route is efficient and immunologically safe, allowing long-term skeletal muscle gene transfer.

Entities:  

Keywords:  AAV; gene transfer; immunogenicity; locoregional delivery; long-term follow-up; nonhuman primate

Year:  2019        PMID: 30808235      PMCID: PMC6648187          DOI: 10.1089/hum.2018.234

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  65 in total

1.  Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy.

Authors:  Glenn P Niemeyer; Roland W Herzog; Jane Mount; Valder R Arruda; D Michael Tillson; John Hathcock; Frederik W van Ginkel; Katherine A High; Clinton D Lothrop
Journal:  Blood       Date:  2008-10-28       Impact factor: 22.113

2.  Early interaction of adeno-associated virus serotype 8 vector with the host immune system following intramuscular delivery results in weak but detectable lymphocyte and dendritic cell transduction.

Authors:  Gwladys Gernoux; Mickaël Guilbaud; Laurence Dubreil; Thibaut Larcher; Candice Babarit; Mireille Ledevin; Nicolas Jaulin; Pierre Planel; Philippe Moullier; Oumeya Adjali
Journal:  Hum Gene Ther       Date:  2015-01       Impact factor: 5.695

3.  Regulatory and Exhausted T Cell Responses to AAV Capsid.

Authors:  Gwladys Gernoux; James M Wilson; Christian Mueller
Journal:  Hum Gene Ther       Date:  2017-04       Impact factor: 5.695

4.  Evidence of multiyear factor IX expression by AAV-mediated gene transfer to skeletal muscle in an individual with severe hemophilia B.

Authors:  Haiyan Jiang; Glenn F Pierce; Margareth C Ozelo; Erich V de Paula; Joseph A Vargas; Peter Smith; Jürg Sommer; Alvin Luk; Catherine S Manno; Katherine A High; Valder R Arruda
Journal:  Mol Ther       Date:  2006-07-05       Impact factor: 11.454

5.  Long-term safety and efficacy of AAV gene therapy in the canine model of glycogen storage disease type Ia.

Authors:  Young Mok Lee; Thomas J Conlon; Andrew Specht; Kirsten E Coleman; Laurie M Brown; Ana M Estrella; Monika Dambska; Kathryn R Dahlberg; David A Weinstein
Journal:  J Inherit Metab Dis       Date:  2018-05-25       Impact factor: 4.982

6.  Long-term effects of systemic gene therapy in a canine model of myotubular myopathy.

Authors:  Matthew Elverman; Melissa A Goddard; David Mack; Jessica M Snyder; Michael W Lawlor; Hui Meng; Alan H Beggs; Ana Buj-Bello; Karine Poulard; Anthony P Marsh; Robert W Grange; Valerie E Kelly; Martin K Childers
Journal:  Muscle Nerve       Date:  2017-05-22       Impact factor: 3.217

7.  Long-term safety and efficacy following systemic administration of a self-complementary AAV vector encoding human FIX pseudotyped with serotype 5 and 8 capsid proteins.

Authors:  Amit C Nathwani; Cecilia Rosales; Jenny McIntosh; Ghasem Rastegarlari; Devhrut Nathwani; Deepak Raj; Sushmita Nawathe; Simon N Waddington; Roderick Bronson; Scott Jackson; Robert E Donahue; Katherine A High; Federico Mingozzi; Catherine Y C Ng; Junfang Zhou; Yunyu Spence; M Beth McCarville; Marc Valentine; James Allay; John Coleman; Susan Sleep; John T Gray; Arthur W Nienhuis; Andrew M Davidoff
Journal:  Mol Ther       Date:  2011-01-18       Impact factor: 11.454

8.  Safety of AAV factor IX peripheral transvenular gene delivery to muscle in hemophilia B dogs.

Authors:  Virginia Haurigot; Federico Mingozzi; George Buchlis; Daniel J Hui; Yifeng Chen; Etiena Basner-Tschakarjan; Valder R Arruda; Antoneta Radu; Helen G Franck; J Fraser Wright; Shangzhen Zhou; Hansell H Stedman; Dwight A Bellinger; Timothy C Nichols; Katherine A High
Journal:  Mol Ther       Date:  2010-04-27       Impact factor: 11.454

9.  Modulation of tolerance to the transgene product in a nonhuman primate model of AAV-mediated gene transfer to liver.

Authors:  Federico Mingozzi; Nicole C Hasbrouck; Etiena Basner-Tschakarjan; Shyrie A Edmonson; Daniel J Hui; Denise E Sabatino; Shangzhen Zhou; J Fraser Wright; Haiyan Jiang; Glenn F Pierce; Valder R Arruda; Katherine A High
Journal:  Blood       Date:  2007-07-03       Impact factor: 22.113

10.  Long-term microdystrophin gene therapy is effective in a canine model of Duchenne muscular dystrophy.

Authors:  Caroline Le Guiner; Laurent Servais; Marie Montus; Thibaut Larcher; Bodvaël Fraysse; Sophie Moullec; Marine Allais; Virginie François; Maeva Dutilleul; Alberto Malerba; Taeyoung Koo; Jean-Laurent Thibaut; Béatrice Matot; Marie Devaux; Johanne Le Duff; Jack-Yves Deschamps; Inès Barthelemy; Stéphane Blot; Isabelle Testault; Karim Wahbi; Stéphane Ederhy; Samia Martin; Philippe Veron; Christophe Georger; Takis Athanasopoulos; Carole Masurier; Federico Mingozzi; Pierre Carlier; Bernard Gjata; Jean-Yves Hogrel; Oumeya Adjali; Fulvio Mavilio; Thomas Voit; Philippe Moullier; George Dickson
Journal:  Nat Commun       Date:  2017-07-25       Impact factor: 14.919

View more
  13 in total

1.  Inherent hepatocytic heterogeneity determines expression and retention of edited F9 alleles post-AAV/CRISPR infusion.

Authors:  Qiang Wang; Lin Zhang; Guo-Wei Zhang; Jian-Hua Mao; Xiao-Dong Xi; Lu Jiang; Gang Lv; Jing Lu; Yan Shen; Zhu Chen; Jiang Zhu; Sai-Juan Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2021-10-19       Impact factor: 11.205

Review 2.  Durability of transgene expression after rAAV gene therapy.

Authors:  Manish Muhuri; Daniel I Levy; Martin Schulz; Douglas McCarty; Guangping Gao
Journal:  Mol Ther       Date:  2022-03-10       Impact factor: 12.910

3.  Intra-CSF AAV9 and AAVrh10 Administration in Nonhuman Primates: Promising Routes and Vectors for Which Neurological Diseases?

Authors:  Karim Bey; Johan Deniaud; Laurence Dubreil; Béatrice Joussemet; Joseph Cristini; Carine Ciron; Juliette Hordeaux; Morwenn Le Boulc'h; Kevin Marche; Maud Maquigneau; Michaël Guilbaud; Rosalie Moreau; Thibaut Larcher; Jack-Yves Deschamps; Marion Fusellier; Véronique Blouin; Caroline Sevin; Nathalie Cartier; Oumeya Adjali; Patrick Aubourg; Philippe Moullier; Marie-Anne Colle
Journal:  Mol Ther Methods Clin Dev       Date:  2020-04-11       Impact factor: 6.698

4.  Long-Term Delivery of an Anti-SIV Monoclonal Antibody With AAV.

Authors:  José M Martinez-Navio; Sebastian P Fuchs; Desiree E Mendes; Eva G Rakasz; Guangping Gao; Jeffrey D Lifson; Ronald C Desrosiers
Journal:  Front Immunol       Date:  2020-03-17       Impact factor: 7.561

5.  AAV8 locoregional delivery induces long-term expression of an immunogenic transgene in macaques despite persisting local inflammation.

Authors:  Gwladys Gernoux; Mickaël Guilbaud; Marie Devaux; Malo Journou; Virginie Pichard; Nicolas Jaulin; Adrien Léger; Johanne Le Duff; Jack-Yves Deschamps; Caroline Le Guiner; Philippe Moullier; Yan Cherel; Oumeya Adjali
Journal:  Mol Ther Methods Clin Dev       Date:  2021-02-06       Impact factor: 6.698

Review 6.  Genetically Engineering the Nervous System with CRISPR-Cas.

Authors:  Alfredo Sandoval; Hajira Elahi; Jonathan E Ploski
Journal:  eNeuro       Date:  2020-03-25

7.  AAVrh10 Vector Corrects Disease Pathology in MPS IIIA Mice and Achieves Widespread Distribution of SGSH in Large Animal Brains.

Authors:  Michaël Hocquemiller; Kim M Hemsley; Meghan L Douglass; Sarah J Tamang; Daniel Neumann; Barbara M King; Helen Beard; Paul J Trim; Leanne K Winner; Adeline A Lau; Marten F Snel; Cathy Gomila; Jérôme Ausseil; Xin Mei; Laura Giersch; Mark Plavsic; Ralph Laufer
Journal:  Mol Ther Methods Clin Dev       Date:  2019-12-10       Impact factor: 6.698

Review 8.  Immune Response Mechanisms against AAV Vectors in Animal Models.

Authors:  Ashley T Martino; David M Markusic
Journal:  Mol Ther Methods Clin Dev       Date:  2019-12-25       Impact factor: 6.698

Review 9.  Externally-Controlled Systems for Immunotherapy: From Bench to Bedside.

Authors:  María Tristán-Manzano; Pedro Justicia-Lirio; Noelia Maldonado-Pérez; Marina Cortijo-Gutiérrez; Karim Benabdellah; Francisco Martin
Journal:  Front Immunol       Date:  2020-09-04       Impact factor: 7.561

10.  Intramuscular injection of vectorized-scFvMC1 reduces pathological tau in two different tau transgenic models.

Authors:  Francesca Vitale; Jasmin Ortolan; Bruce T Volpe; Philippe Marambaud; Luca Giliberto; Cristina d'Abramo
Journal:  Acta Neuropathol Commun       Date:  2020-08-06       Impact factor: 7.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.